LifeSci Capital Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Maintains Target Price $8
Truist Financial Maintains Mersana Therapeutics(MRSN.US) With Buy Rating
LifeSci Capital Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Maintains Target Price $8
Buy Rating for Mersana Therapeutics: Promising ADC Developments and Strategic Market Positioning
Truist Financial Maintains Mersana Therapeutics(MRSN.US) With Buy Rating
Truist Financial Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Announces Target Price $9
Truist Financial Sticks to Its Buy Rating for Mersana Therapeutics (MRSN)
Mersana Therapeutics Is Maintained at Buy by Citigroup
Mersana Therapeutics Price Target Cut to $5.00/Share From $6.00 by Citigroup
Citi Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Maintains Target Price $5
Analysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP), Chimerix (CMRX) and Mersana Therapeutics (MRSN)
Mersana Therapeutics Analyst Ratings
Baird Maintains Neutral on Mersana Therapeutics, Lowers Price Target to $3
BTIG Initiates Mersana Therapeutics(MRSN.US) With Buy Rating, Announces Target Price $6
Truist Financial Issues a Buy Rating on Mersana Therapeutics (MRSN)
Truist Financial Maintains Mersana Therapeutics(MRSN.US) With Buy Rating
Buy Rating on Mersana Therapeutics: Advancing XMT-1660 Program and Promising Tolerability Profile
TD Cowen Sticks to Its Buy Rating for Mersana Therapeutics (MRSN)
TD Cowen Maintains Mersana Therapeutics(MRSN.US) With Buy Rating
Truist Financial Sticks to Its Buy Rating for Mersana Therapeutics (MRSN)